Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 12, Issue 1, 2009, Pages 46-78

  Bansal, Tripta ^a   Jaggi, Manu ^a   Khar, Roop K ^b   Talegaonkar, Sushama ^b  

^a DABUR RESEARCH FOUNDATION   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AURANTIIN; BAICALEIN; CYCLOSPORIN A; DIGOXIN; DILTIAZEM; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; FLAVONE; FLAVONOID; GLYCOPROTEIN P INHIBITOR; HERBACEOUS AGENT; IRINOTECAN; KAEMPFEROL; MOXIDECTIN; NAVELBINE; PACLITAXEL; QUERCETIN; QUININE; TAMOXIFEN; TARIQUIDAR; TRIFLUOPERAZINE; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; VINCRISTINE; ZOSUQUIDAR; GLYCOPROTEIN P;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BRAIN TUMOR; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CYTOTOXICITY TEST; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UPTAKE; HUMAN; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ARTICLE; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; DRUG INTERACTION; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG DESIGN; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; P-GLYCOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69949106198     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3rc77     Document Type: Review

References (203)

1. Krishna, R., and Mayer, L. D. Multidrug resistance (MDR) in cancer mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci., 11: 265-283, 2000.
2. Juliano, R. L., and Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455: 152-162, 1976.
3. Schinkel, A. H., and Jonker, J. W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev., 55: 3-29, 2003.
4. Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramchandra, M., Pastan, I., and Gottesman, M. M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 39: 361-398, 1999.
5. Benet, L. Z., and Cummins, C. L. The drug efflux-metabolism alliance: biochemical aspects. Journees Galeniques, 94: 9-16, 2001.
6. Hunter, J., and Hirst, B. H. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv. Drug Del. Rev., 25: 129-157, 1997.
7. Polli, J. W., Wring, S. A., Humphreys, J. E., Huang, L., Morgan, J. B., Webster, L. O., and Singh, C. S. S. Rational use of in vitro Pglycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther., 299: 620-628, 2001.
8. Tandon, V. R., Kapoor, B., Bano, G., Gupta, S., Gillani, Z., Gupta, S., and Kour, D. Pglycoprotein: Pharmacological relevance. Indian J Pharmacol, 38: 13-24, 2006
9. Varma, M. V., Perumal, O. P., and Panchagnula, R. Functional role of Pglycoprotein in limiting peroral drug absorption: optimizing drug delivery. Curr Opin Chem Biol, 10: 367-373, 2006.
10. Lin, J. H. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev., 55: 53-81, 2003.
11. Dantzig, A. H., Shepard, R. L., Cao, J., Law, K. L., Ehlhardt, W. J., Baughman, T. M., Bumol, T. F., and Starling, J. J. Reversal of Pglycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res, 56: 4171-4179, 1996.
12. Hyafil, F., Vergely, C., Du Vignaud, P., and Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res, 53: 4595-4602, 1993.
13. Breedveld, P., Beijnen, J. H., and Schellens, J. H. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci, 27: 17-24, 2006.
14. Dantzig, A. H., de Alwis, D. P., and Burgess, M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev, 55: 133-150, 2003.
15. Loo, T. W., and Clarke, D. M. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol, 206: 173-185, 2005.
16. Booth, C. L., Pulaski, L., Gottesman, M. M., and Pastan, I. Analysis of the properties of the N-terminal nucleotide-binding domain of human P-glycoprotein. Biochemistry, 39: 5518-5526, 2000.
17. Tombline, G., Bartholomew, L., Gimi, K., Tyndall, G. A., and Senior, A. E. Synergy between conserved ABC signature Ser residues in P-glycoprotein catalysis. J Biol Chem 279: 5363-5373, 2004.
18. Ambudkar, S. V., Kim, I. W., and Sauna, Z. E. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci, 27: 392-400, 2006.
19. Yasuhisa, K., Michinori, M., Kei, T., Tohru, S., and Noriyuki, K. ATP hydrolysis dependent multidrug efflux transporter: MDR1/P-glycoprotein. Current Drug Metabolism, 5: 1-10, 2004.
20. Thiebaut, F., Tsumo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. C. Cellular localisation of the multidrug resistance gene product Pglycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA, 84: 7735-7738, 1987.
21. Croop, J. M., Raymond, M., Haber, D., A., D., Arceci, R. J., Gros, P., and Housman, D. E. The three mouse multidmg resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol. Cell. Biol., 9: 1346-1350, 1989.
22. Arceci, R. J., Croop, J. M., Horwitz, S., and Housman, D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc. Natl. Acad. Sci. USA, 85: 4350-4354, 1988.
23. Joly, B., Fardel, O., Cecchelli, R., Chesn, C., Puozzo, C., and Guillouzo, A. Selective drug transport and P-glycoprotein activity in an in vitro blood-brain barrier model. Tox. In Vitro, 9: 357-364, 1995.
24. Fardel, O., Lecureur, V., and Guillouzo, A. The P-Glycoprotein Multidrug Transporter. Gen. Pharmac., 27: 1283-1291, 1996.
25. Ito, K., Suzuki, H., Horie, T., and Sugiyama, Y. Apical/Basolateral Surface Expression of Drug Transporters and its Role in Vectorial Drug Transport. Pharm Res, 22: 1559-1577, 2005.
26. Drach, D., Zhao, S., Drach, J., and Anoheeff, M. Low incidence of MDR1 expression in acute promyelocytic leukaemia. Br. J. Haematol., 90: 369-374, 1995.
27. Abolhoda, A., Wilson, A. E., Ross, H., Danenberg, P. V., Burt, M., and Scotto, K. W. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res., 5: 3352-3356, 1999.
28. Thomas, H., and Coley, H. M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting Pglycoprotein. Cancer Control, 10: 159-165, 2003.
29. Ino, T., Miyazaki, H., Isogar, M., Nomura, T., Tsuzuki, M., Tsuruo, T., Ezaki, K., and Hirano, M. Expression of P glycoprotein in de now) acute myclogenous leukemia at initial diagnosis: results of molecular and functional assays and correlation with treatment outcome. Leukemia, 8: 1492-1497, 1994
30. Ozben, T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Letters 580: 2903-2909, 2006.
31. Ueda, K., Taguchi, Y., and Morishima, M. How does P-glycoprotein recognize its substrates. Semin Cancer Biol 8: 151-159, 1997.
32. Sauna, Z. E., and Ambudkar, S. V. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Natl Acad Sci, 97: 2515-2520, 2000.
33. Varma, M., Ashokraj, Y., Dey, C. S., and Panchagnula, R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res., 48: 347-359, 2003.
34. Sharom, F. J. The P-glycoprotein efflux pumps: how does it transport drugs? J. Memb. Bio., 160: 161-175, 1997.
35. Rosenberg, M. F., Kamis, A. B., Collaghan, R., Higgins, C. F., and Ford, R. C. Threedimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem, 278: 8294-8299, 2003.
36. Sauna, Z. E., Smith, M. M., Muller, M., Kerr, K. M., and Ambudkar, S. V. The mechanism of action of multidrug-resistance-linked Pglycoprotein. J. Bioener. Biomemb., 33: 481-491, 2001.
37. Loo, T. W., and Clarke, D. M. Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"? Biochem Biophys Res Commun, 329: 419-422, 2005.
38. Tsuruo, T., Iida, H., Tsukagoshi, S., and Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res., 41: 1967-1972, 1981.
39. Schoenhard, G. L., Inhibitors of ABC drug transporters at the blood-brain barrier Pain Therapeutics, Inc., US patent No. 7,034,036 (2006).
40. Liscovitch, M., and Lavie, Y. Cancer multidrug resistance: A review of recent drug discovery research. IDrugs, 5: 1-7, 2002.
41. Dintaman, J. M., and Silverman, J. A. Inhibition of P-glycoprotein by D-alphatocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res., 16: 1550-1556, 1999.
42. Huang, J., Si, L., Jiang, L., Fan, Z., Qiu, J., and Li, G. Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. Int J Pharm, 356: 351-353, 2008.
43. Kabanova, A. V., Batrakova, E. V., and Alakhov, V. Y. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev, 54: 759-779, 2002.
44. Zhou, S., Lim, L. Y., and Chowbay, B. Herbal modulation of P-glycoprotein. Drug Metab Rev, 36: 57-104, 2004.
45. Rege, B. D., Kao, J. P. Y., and Polli, J. E. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci, 16: 237-246, 2002.
46. Regev, R., Katzir, H., Yeheskely-Hayon, D., and Eytan, G. D. Modulation of Pglycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane. FEBS J., 274: 6204-6214, 2007.
47. Buggins, T. R., Dickinson, P. A., and Taylor, G. The effects of pharmaceutical excipients on drug disposition. Adv Drug Deliv Rev, 59: 1482-1503, 2007.
48. Deferme, S., and Augustijns, P. The effects of food components on the absorption of P-gp substrates: a review. J. Pharm. Pharmacol., 55: 153-162, 2003.
49. Deferme, S., Gelder, J. V., and Augustijns, P. Inhibitory effect of fruit extracts on Pglycoprotein related efflux carriers: an in vitro screening. J. Pharm. Pharmacol., 54: 1213-1219, 2002.
50. Brand, W., Schutte, M. E., Williamson, G., van Zanden, J. J., Cnubben, N. H., Groten, J. P., van Bladeren, P. J., and Rietjens, I. M. Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed Pharmacother, 60: 508-519, 2006.
51. Chavez, M. L., Jordan, M. A., and Chavez, P. I. Evidence-based drug--herbal interactions. Life Sci, 78: 2146-2157, 2006.
52. Cornaire, G., Woodley, J., Hermann, P., Cloarec, A., Arellano, C., and Houin, G. Impact of excipients on the absorption of Pglycoprotein substrates in vitro and in vivo. Int J Pharm, 278: 119-131, 2004.
53. Marchetti, S., Mazzanti, R., Beijnen, J. H., and Schellens, J. H. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist, 12: 927-941, 2007.
54. Morris, M. E., and Zhang, S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci, 78: 2116-2130, 2006.
55. Pal, D., and Mitra, A. K. MDR-and CYP3A4-mediated drug-herbal interactions. Life Sci, 78: 2131-2145, 2006.
56. Yang, C. Y., Chao, P. D., Hou, Y. C., Tsai, S. Y., Wen, K. C., and Hsiu, S. L. Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats. Food Chem Toxicol, 44: 1572-1578, 2006.
57. Yoshida, N., Takagi, A., Kitazawa, H., Kawakami, J., and Adachi, I. Inhibition of Pglycoprotein-mediated transport by extracts of and monoterpenoids contained in Zanthoxyli fructus. Toxicol Appl Pharmacol, 209: 167-173, 2005.
58. Zhou, S. F., Zhou, Z. W., Li, C. G., Chen, X., Yu, X., Xue, C. C., and Herington, A. Identification of drugs that interact with herbs in drug development. Drug Discov Today, 12: 664-673, 2007.
59. Bailey, D., Spence, J., Munoz, C., and Arnold, J. Interaction of citrus juices with felodipine and nifedipine. Lancet, 337: 268-269, 1991.
60. Zhou, S. F., and Lai, X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr Drug Metab, 9: 394-409, 2008.
61. Peng, S. X., Ritchie, D. M., Cousineau, M., Danser, E., Dewire, R., and Floden, J. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. J Pharm Sci, 95: 1984-1993, 2006.
62. Evans, A. M. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther. Drug Monit., 22: 131-136, 2000.
63. Walter-Sack, I., and Klotz, U. Influence of diet and nutritional status on drug metabolism. Clin. Pharmacokinet., 31: 47-64, 1996.
64. Wilkinson, G. R. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv. Drug Deliv. Rev., 27: 129-159, 1997.
65. Zhou, S. F., Gao, Y. H., Wen, Q. J., Huang, M., Xu, A. L., and Paxton, J. W. Interactions of herbs with cytochrome P450. Drug Metab. Rev., 35: 35-98, 2003.
66. Laitinen, L. A., Tammela, P. S., Galkin, A., Vuorela, H. J., Marvola, M. L., and Vuorela, P. M. Effects of extracts of commonly consumed food supplements and food fractions on the permeability of drugs across Caco-2 cell monolayers. Pharm Res, 21: 1904-1916, 2004.
67. Piao, Y., Shin, S. C., and Choi, J. S. Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats. Biopharm Drug Dispos, 29: 245-249, 2008.
68. Zhang, S., Yang, X., and Morris, M. E. Flavonoids Are Inhibitors of Breast Cancer Resistance Protein (ABCG2)-Mediated Transport. Mol Pharmacol, 65: 1208-1216, 2004.
69. Havsteen, B. H. The biochemistry and medical significance of the flavonoids. Pharmacol Ther, 96: 67-202, 2002.
70. Romiti, N., Tongiani, R., Cervelli, F., and Chieli, E. Effects of curcumin on Pglycoprotein in primary cultures of rat hepatocytes. Life Sci., 62: 2349-2358, 1998.
71. Anuchapreeda, S., Leechanachai, P., Smith, M. M., Ambudkar, S. V., and Limtrakul, P. N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol, 64: 573-582, 2002.
72. Foster, B. C., Foster, M. S., Vandenhoek, S., Krantis, A., Budzinski, J. W., Arnason, J. T., Gallicano, K. D., and Choudri, S. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J. Pharm. Pharm. Sci., 4: 176-184, 2001.
73. Kim, S. W., Kwon, H. Y., Chi, D. W., Shim, J. H., Park, J. D., Lee, Y. H., Pyo, S., and Rhee, D. K. Reversal of P-glycoproteinmediated multidrug resistance by ginsenoside Rg(3). Biochem. Pharmacol., 65: 75-82, 2003.
74. Ikegawa, T., Ushigome, F., Koyabu, N., Morimoto, S., Shoyama, Y., Naito, M., Tsuruo, T., Ohtani, H., and Sawada, Y. Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett, 160: 21-28, 2000.
75. Spahn-Langguth, H., and Langguth, P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur. J. Pharm. Sci., 12: 361-367, 2001.
76. Takanaga, H., Ohnishi, A., Matsuo, H., and Sawada, Y. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull, 21: 1062-1066, 1998.
77. Tian, R., Koyabu, N., Takanaga, H., Matsuo, H., Ohtani, H., and Sawada, Y. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res, 19: 802-809, 2002.
78. Sadzuka, Y., Sugiyama, T., and Sonobe, T. Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance. Toxicol. Lett., 114: 155-162, 2000.
79. Jodoin, J., Demeule, M., and Beliveau, R. Inhibition of the multidrug resistance Pglycoprotein activity by green tea polyphenols. Biochim Biophys Acta, 1542: 149-159, 2002.
80. Zhang, S., and Morris, M. E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther, 304: 1258-1267, 2003.
81. Bhardwaj, R. K., Glaeser, H., Becquemont, L., Klotz, U., Gupta, S. K., and Fromm, M. F. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther, 302: 645-650, 2002.
82. Durr, D., Stieger, B., Kullak-Ublick, G. A., Rentsch, K. M., Steinert, H. C., Meier, P. J., and Fattinger, K. St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther., 68: 598-604, 2000.
83. Hennessy, M., Kelleher, D., Spiers, J. P., Barry, M., Kavanagh, P., Back, D., Mulcahym, F., and Feely, J. St. John's wort increases expression of P-glycoprotein: implications for drug interactions. Br. J. Clin. Pharmacol., 53: 75-82, 2002.
84. Perloff, M. D., von Moltke, L. L., Stormer, E., Shader, R. I., and Greenblatt, D. J. Saint John's wort: an in vitro analysis of Pglycoprotein induction due to extended exposure. Br. J. Pharmacol., 134: 1601-1608, 2001.
85. Mathijssen, R. H., Verweij, J., de Bruijn, P., Loos, W. J., and Sparreboom, A. Effects of St. John's wort on irinotecan metabolism. J. Natl. Cancer Inst., 94: 1247-1249, 2002.
86. Hu, Z., Yang, X., Ho, P. C., Chan, E., Chan, S. Y., Xu, C., Li, X., Zhu, Y. Z., Duan, W., Chen, X., Huang, M., Yang, H., and Zhou, S. St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharm Res, 22: 902-914, 2005.
87. Plouzek, C. A., Ciolino, H. P., Clarke, R., and Yeh, G. C. Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. Eur. J. Cancer, 35: 1541-1545, 1999.
88. Narayana, K. R., Reddy, M. S., Chaluvadi, M. R., and Krishna, D. R. Bioflavonoids classification, pharmacological, biochemical effects and therapeutic potential. Ind. J Pharmacol., 33: 2-16, 2001.
89. Ross, S. A., Ziska, D. S., Zhao, K., and ElSohly, M. A. Variance of common flavonoids by brand of grapefruit juice. Fitoterapia, 71: 154-161, 2000.
90. Manach, C., Morand, C., Gil-Izquierdo, A., Bouteloup-Demange, C., and Remesy, C. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. European Journal of Clinical Nutrition, 57: 235-242, 2003.
91. Dupuy, J., Larrieu, G., Sutra, J. F., Lespine, A., and Alvinerie, M. Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet Parasitol, 112: 337-347, 2003.
92. Zhang, H., Wong, C. W., Coville, P. F., and Wanwimolruk, S. Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats. Drug Metabolism and Drug Interactons, 17: 351-363, 2000.
93. Lai, M. Y., Hsiu, S. L., Hou, Y. C., Tsai, S. Y., and Chao, P. D. Significant decrease of cyclosporine bioavailability in rats caused by a decoction of the roots of Scutellaria baicalensis. Planta Medica, 70: 132-137, 2004.
94. Choi, J. S., Choi, H. K., and Shin, S. C. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int J Pharm, 275: 165-170, 2004.
95. Choi, J. S., Jo, B. W., and Kim, Y. C. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm, 57: 313-318, 2004.
96. Wang, Y. H., Chao, P. D., Hsiu, S. L., Wen, K. C., and Hou, Y. C. Lethal quercetin digoxin interaction in pigs. Life Sci, 74: 1191-1197, 2004.
97. Ikegawa, T., Ohtani, H., Koyabu, N., Juichi, M., Iwase, Y., Ito, C., Furukawa, H., Naito, M., Tsuruo, T., and Sawada, Y. Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett, 177: 89-93, 2002.
98. Mitsunaga, Y., Takanaga, H., Matsuo, H., Naito, M., Tsuruo, T., Ohtani, H., and Sawada, Y. Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur J Pharmacol, 395: 193-201, 2000.
99. Chieli, E., Romiti, N., Cervelli, F., and Tongiani, R. Effects of flavonols on Pglycoprotein activity in cultured rat hepatocytes. Life Sci, 57: 1741-1751, 1995.
100. Ohtani, H., Ikegawa, T., Honda, Y., Kohyama, N., Morimoto, S., Shoyama, Y., Juichi, M., Naito, M., Tsuruo, T., and Sawada, Y. Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-gpoverexpressing K562/ADM cells. Pharm Res, 24: 1936-1943, 2007.
101. Shin, S. C., Choi, J. S., and Li, X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm, 313: 144-149, 2006.
102. Choi, J. S., and Shin, S. C. Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. Int J Pharm, 292: 149-156, 2005.
103. Youdim, K. A., Qaiser, M. Z., Begley, D. J., Rice-Evans, C. A., and Abbott, N. J. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med, 36: 592-604, 2004.
104. Kitagawa, S., Nabekura, T., and Kamiyama, S. Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J Pharm Pharmacol, 56: 1001-1005, 2004.
105. Takanaga, H., Ohnishi, A., Yamada, S., Matsuo, H., Morimoto, S., Shoyama, Y., Ohtani, H., and Sawada, Y. Polymethoxylated flavones in orange juice are inhibitors of Pglycoprotein but not cytochrome P450 3A4. J Pharmacol Exp Ther, 293: 230-236, 2000.
106. Scambia, G., Ranelletti, F. O., Panici, P. B., De Vincenzo, R., Bonanno, G., Ferrandina, G., Piantelli, M., Bussa, S., Rumi, C., Cianfriglia, M., and et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breastcancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol, 34: 459-464, 1994.
107. Castro, A. F., and Altenberg, G. A. Inhibition of drug transport by genistein in multidrugresistant cells expressing P-glycoprotein. Biochem Pharmacol, 53: 89-93, 1997.
108. Edwards, D. J., Fitzsimmons, M. E., Schuetz, E. G., Yasuda, K., Ducharme, M. P., Warbasse, L. H., Woster, P. M., Schuetz, J. D., and Watkins, P. 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and Pglycoprotein. Clin Pharmacol Ther, 65: 237-244, 1999.
109. Jeong, J. M., and Choi, C. H. Enhancement of paclitaxel transport and cytotoxicity by 7,3',4'-trimethoxyflavone, a P-glycoprotein inhibitor. J Pharm Pharm Sci, 10: 547-553, 2007.
110. Yoshikawa, M., Ikegami, Y., Sano, K., Yoshida, H., Mitomo, H., Sawada, S., and Ishikawa, T. Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J Exp Ther Oncol, 4: 25-35, 2004.
111. Li, X., and Choi, J. S. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. Int J Pharm, 337: 188-193, 2007.
112. Bansal, T., Awasthi, A., Jaggi, M., Khar, R. K., and Talegaonkar, S. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of Pglycoprotein. Life Sci, 83: 250-259, 2008.
113. Lin, L. C., Wang, M. N., and Tsai, T. H. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38. Chem Biol Interact, 174: 177-182, 2008.
114. Limtrakul, P., Khantamat, O., and Pintha, K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother, 17: 86-95, 2005.
115. Regev, R., Assaraf, Y. G., and Eytan, G. D. Membrane fluidization by ether, other anesthetics, and certain agents abolishes Pglycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur J Biochem, 259: 18-24, 1999.
116. Sachs-Barrable, K., Thamboo, A., Lee, S. D., and Wasan, K. M. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J Pharm Pharm Sci, 10: 319-331, 2007.
117. Maki, N., Hafkemeyer, P., and Dey, S. Allosteric modulation of human Pglycoprotein. Inhibition of transport by preventing substrate translocation and dissociation. J Biol Chem, 278: 18132-18139, 2003.
118. Watkins, R. E., Maglich, J. M., Moore, L. B., Wisely, G. B., Noble, S. M., Davis-Searles, P. R., Lambert, M. H., Kliewer, S. A., and Redinbo, M. R. A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry, 42: 1430-1438, 2003.
119. Drori, S., Eytan, G. D., and Assaraf, Y. G. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem, 228: 1020-1029, 1995.
120. Arora, A., Byrem, T. M., Nair, M. G., and Strasburg, G. M. Modulation of liposomal membrane fluidity by flavonoids and isoflavonoids. Arch Biochem Biophys, 373: 102-109, 2000.
121. Shapiro, A. B., and Ling, V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol, 53: 587-596, 1997.
122. Boumendjel, A., Di Pietro, A., Dumontet, C., and Barron, D. Recent advances in the discovery of flavonoids and analogues with high affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med. Res. Rev., 22: 512-529, 2002.
123. Tamai, I., and Safa, A. R. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem, 266: 16796-16800, 1991.
124. Conseil, G., Baubichon-Cortay, H., Dayan, G., Jault, J. M., Barron, D., and Di Pietro, A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP-and steroid-binding sites on mouse Pglycoprotein. Proc Natl Acad Sci USA, 95: 9831-9836, 1998.
125. Boumendjel, A., Beney, C., Deka, N., Mariotte, A. M., Lawson, M. A., Trompier, D., Baubichon-Cortay, H., and Di Pietro, A. 4-Hydroxy-6-methoxyaurones with highaffinity binding to cytosolic domain of Pglycoprotein. Chem. Pharm. Bull., 50: 854-856, 2002.
126. Critchfield, J. W., Welsh, C. J., Phang, J. M., and Yeh, G. C. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells: activation of Pglycoprotein as a putative mechanism. Biochem. Pharmacol., 48: 1437-1445, 1994.
127. Phang, J. M., Poore, C. M., Lopaczynska, J., and Yeh, G. C. Flavonol stimulated efflux of 7,12-dimethylbenz(a)-anthracene in multidrug-resistant breast cancer cells. Cancer Res., 53: 5977-5981, 1993.
128. Ferté, J., Kühnel, J.-M., Chapuis, G., Rolland, Y., Lewin, G., and Schwaller, M. A. Flavonoid-related modulators of multidrug resistance: synthesis, pharmacological activity, and structure activity relationships. J. Med. Chem., 42: 478-489, 1999.
129. Chiba, P., Holzer, W., Landau, M., Bechmann, G., Lorenz, K., Plagens, B., Hitzler, M., Richter, E., and Ecker, G. Substituted 4-acylpyrazoles and 4-acylpyrazolones: synthesis and multidrug resistance-modulating activity. J. Med. Chem., 41: 4001-4011, 1998.
130. Ecker, G., Huber, M., Schmid, D., and Chiba, P. The importance of a nitrogen atom in modulators of multidrug resistance. Mol. Pharmacol. Res., 56: 791-796, 1999.
131. Hiessbock, R., Wolf, C., Richter, E., Hitzler, M., Chiba, P., Kratzel, M., and Ecker, G. Synthesis and in vitro multidrug resistance modulating activity of a series of dihydrobenzopyrans and tetrahydroquinolines. J. Med. Chem., 42: 1921-1926, 1999.
132. Versantvoort, C. H. M., Schuurhuis, G. J., Pinedo, H. M., Eekman, C. A., Kuiper, C. M., Lankelma, J., and Broxterman, H. J. Genistein modulates the decreased drug accumulation in non P-glycoprotein mediated multidrug resistant tumour cells. Br. J. Cancer, 68: 939-946, 1993.
133. Hadjeri, M., Barbier, M., Ronot, X., Mariotte, A. M., Boumendjel, A., and Boutonnat, J. Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues. J Med Chem, 46: 2125-2131, 2003.
134. Comte, G., Daskiewicz, J.-B., Bayet, C., Conseil, G., Vornery-Vanier, A., Dumontet, C., Di Pietro, A., and Barron, D. Cisoprenylation of flavonoids enhances affinity toward P-glycoprotein and modulation of cancer cell chemoresistance. J. Med. Chem., 44: 763-768, 2001.
135. Cooray, H. C., Janvilisri, T., van Veen, H. W., Hladky, S. B., and Barrand, M. A. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun., 317: 269-275, 2004.
136. van Zanden, J. J., Wortelboer, H. M., Bijlsma, S., Punt, A., Usta, M., Bladeren, P. J., Rietjens, I. M., and Cnubben, N. H. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem. Pharmacol., 69: 699-708, 2005.
137. Guengerich, F. P., and Kim, H. D. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis, 11: 2275-2279, 1990.
138. Miniscalco, A., Landahl, J., Regardh, C. G., Edgar, B., and Eriksson, U. G. Inhibition of dihydropyridine in rat and human liver microsomes by flavonoids found in grapefruit juice. J. Pharmacol. Exp. Ther., 261: 1195-1198, 1992.
139. Hsiu, S. L., Hou, Y. C., Wang, Y. H., Tsao, C. W., Su, S. F., and Chao, P. D. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci, 72: 227-235, 2002.
140. Shapiro, A. B., and Ling, V. Stoichiometry of coupling of rhodamine 123 transporter to hydrolysis by human P glycoprotein. Eur J Biochem, 254: 189-193, 1998.
141. Broder, S., Duchin, K. L., and Selim, S., Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents Baker Norton Pharmaceuticals, Inc., US Patent No. 7,041,640 (2006).
142. Inomata, K., Takahashi, T., Inoue, H., Yanai, M., Yamazaki, H., Suzuki, M., Takasawa, T., Kawamura, K., Oshida, N., Ikemoto, H., and Kishiye, T., Multidrug resistance inhibitors, Nisshin Flour Milling Co., Ltd., US Patent No. 6,011,069 (2000).
143. Schellens, J. H. M., and Schinkel, A. H., Method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs, Cancer Research Ventures Limited, US Patent No. 7,030,132 (2006).
144. Schinkel, A. H., Mol, C. A., Wagenaar, E., van Deemter, L., Smit, J. J., and Borst, P. Multidrug resistance and the role of Pglycoprotein knockout mice. Eur J Cancer, 31A: 1295-1298, 1995.
145. Breedveld, P., Pluim, D., Cipriani, G., Wielinga, P., van Tellingen, O., Schinkel, A. H., and Schellens, J. H. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res, 65: 2577-2582, 2005.
146. Allen, J. D., Van Dort, S. C., Buitelaar, M., van Tellingen, O., and Schinkel, A. H. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res, 63: 1339-1344, 2003.
147. Leu, B. L., and Huang, J. D. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother. Pharmacol., 35: 432-436, 1995.
148. Creemers, G. J., Gerrits, C. J., Eckardt, J. R., Schellens, J. H., Burris, H. A., Planting, A. S., Rodriguez, G. I., Loos, W. J., Hudson, I., Broom, C., Verweij, J., and Von Hoff, D. D. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol, 15: 1087-1093, 1997.
149. Jonker, J. W., Smit, J. W., Brinkhuis, R. F., Maliepaard, M., Beijnen, J. H., Schellens, J. H., and Schinkel, A. H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst, 92: 1651-1656, 2000.
150. Zamboni, W. C., Bowman, L. C., Tan, M., Santana, V. M., Houghton, P. J., Meyer, W. H., Pratt, C. B., Heideman, R. L., Gajjar, A. J., Pappo, A. S., and Stewart, C. F. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol, 43: 454-460, 1999.
151. Borst, P., and Schinkel, A. H. Genetic dissociation of the function of mammalian Pglycoproteins. Trends Genet, 13: 217-222, 1997.
152. Meerum Terwogt, J. M., Beijnen, J. H., ten Bokkel Huinink, W. W., Rosing, H., and Schellens, J. H. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet, 352: 285, 1998.
153. Schinkel, A. H., Smit, J. J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P., and et al. Disruption of the mouse mdr1a Pglycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77: 491-502, 1994.
154. Sparreboom, A., Asperen, J. V., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Nooijen, W. J., Beijnen, J. H., and Tellingen, O. V. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA, 94: 2031-2035, 1997.
155. van Asperen, J., van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijen, W. J., and Beijnen, J. H. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer, 76: 1181-1183, 1997.
156. Malingre, M. M., Richel, D. J., Beijnen, J. H., Rosing, H., Koopman, F. J., Ten Bokkel Huinink, W. W., Schot, M. E., and Schellens, J. H. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol, 19: 1160-1166, 2001.
157. Hsiao, P., Bui, T., Ho, R. J., and Unadkat, J. D. In vitro-to-in vivo prediction of Pglycoprotein-based drug interactions at the human and rodent blood-brain barrier. Drug Metab Dispos, 36: 481-484, 2008.
158. Syvanen, S., Hooker, A., Rahman, O., Wilking, H., Blomquist, G., Langstrom, B., Bergstrom, M., and Hammarlund-Udenaes, M. Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. J Pharm Sci, 97: 5386-5400, 2008.
159. Fellner, S., Bauer, B., Miller, D. S., Schaffrik, M., Fankhanel, M., Spruss, T., Bernhardt, G., Graeff, C., Farber, L., Gschaidmeier, H., Buschauer, A., and Fricker, G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest, 110: 1309-1318, 2002.
160. Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J. H., Borst, P., and Schinkel, A. H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier Pglycoprotein by oral treatment of mice with PSC833. J. Clin. Invest., 100: 2430-2436, 1997.
161. Schinkel, A. H., Wagenaar, E., Mol, C. A. A. M., and van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest., 97: 2517-2524, 1996.
162. Hsieh, Y. J., Chang, C. H., Huang, S. P., Lin, C. W., Wang, M. N., Wu, Y. T., Chen, Y. J., and Tsai, T. H. Effect of cyclosporin A on the brain regional distribution of doxorubicin in rats. Int J Pharm, 350: 265-271, 2008.
163. Bihorel, S., Camenisch, G., Lemaire, M., and Scherrmann, J. M. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res, 24: 1720-1728, 2007.
164. Dai, H., Marbach, P., Lemaire, M., Hayes, M., and Elmquist, W. F. Distribution of STI-571 to the brain is limited by P-glycoprotein mediated efflux. J Pharmacol Exp Ther, 304: 1085-1092, 2003.
165. Decleves, X., Bihorel, S., Debray, M., Yousif, S., Camenisch, G., and Scherrmann, J. M. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells. Pharmacol Res, 57: 214-222, 2008.
166. Hamada, A., Miyano, H., Watanabe, H., and Saito, H. Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther, 307: 824-828, 2003.
167. Bosch, T. M. Pharmacogenomics of drugmetabolizing enzymes and drug transporters in chemotherapy. Methods Mol Biol, 448: 63-76, 2008.
168. Walle, T., Walle, K., Kumar, G. N., and Bhalla, K. N. Taxol metabolism and disposition in cancer patients. Drug Metabol Dispos, 23: 506-512, 1995.
169. Schellens, J. H. M., Malingre, M. M., Marielle, C., Kruijtzera, F., Bardelmeijera, H. A., van Tellingen, O., Schinkel, A. H., and Beijnen, J. H. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci, 12: 103-110, 2000.
170. Iyer, L., Ramirez, J., Shepard, D. R., Bingham, C. M., Hossfeld, D. K., Ratain, M. J., and Mayer, U. Biliary transport of irinotecan and metabolites in normal and Pglycoprotein-deficient mice. Cancer Chemother Pharmacol, 49: 336-341, 2002.
171. Tobin, P. J., Hong, Y., Seale, J. P., Rivory, L. P., and McLachlan, A. J. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver. J Pharm Pharmacol, 57: 39-45, 2005.
172. Chico, I., Kang, M. H., Bergan, R., Abraham, J., Bakke, S., Meadows, B., Rutt, A., Robey, R., Choyke, P., Merino, M., Goldspiel, B., Smith, T., Steinberg, S., Figg, W. D., Fojo, T., and Bates, S. Phase I study of infusional paclitaxel in combination with the Pglycoprotein antagonist PSC 833. J Clin Oncol, 19: 832-842, 2001.
173. Meerum Terwogt, J. M., Malingre, M. M., Beijnen, J. H., ten Bokkel Huinink, W. W., Rosing, H., Koopman, F. J., van Tellingen, O., Swart, M., and Schellens, J. H. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res, 5: 3379-3384, 1999.
174. Mistry, P., Stewart, A. J., Dangerfield, W., Okiji, S., Liddle, C., Bootle, D., Plumb, J. A., Templeton, D., and Charlton, P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res, 61: 749-758, 2001.
175. Newman, M. J., Rodarte, J. C., Benbatoul, K. D., Romano, S. J., Zhang, C., Krane, S., Moran, E. J., Uyeda, R. T., Dixon, R., Guns, E. S., and Mayer, L. D. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res, 60: 2964-2972, 2000.
176. Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P., Villalona, M., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L., Kraynak, M., Drengler, R., Stephenson, J., Jr., Harding, M. W., and Von Hoff, D. D. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol, 16: 2964-2976, 1998.
177. Giaccone, G., Linn, S. C., Welink, J., Catimel, G., Stieltjes, H., van der Vijgh, W. J., Eeltink, C., Vermorken, J. B., and Pinedo, H. M. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res, 3: 2005-2015, 1997.
178. Sparreboom, A., Planting, A. S., Jewell, R. C., van der Burg, M. E., van der Gaast, A., de Bruijn, P., Loos, W. J., Nooter, K., Chandler, L. H., Paul, E. M., Wissel, P. S., and Verweij, J. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs, 10: 719-728, 1999.
179. Horio, M., Chin, K. V., Currier, S. J., Goldenberg, S., Willams, C., Pastan, I., Gottesman, M. M., and Handler, J. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J. Biol. Chem., 264 14880-14884, 1989.
180. Arimori, K., Kuroki, N., Hidaka, M., Iwakiri, T., Yamsaki, K., Okumura, M., Ono, H., Takamura, N., Kikuchi, M., and Nakano, M. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm Res, 20: 910-917, 2003.
181. Gupta, E., Safa, A. R., Wang, X., and Ratain, M. J. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res, 56: 1309-1314, 1996.
182. Huang, S., and Lesko, L. J. Drug-Drug, Drug-Dietary Supplement, and Drug-Citrus Fruit and Other Food Interactions: What Have We Learned? J Clin Pharmacol, 44: 559-569, 2004.
183. Wagner, D., Spahn-Langguth, H., Hanafy, A., Koggel, A., and Langguth, P. Intestinal drug efflux: formulation and food effects. Adv. Drug Deliv. Rev., 50 Suppl 1: S13-31., 2001.
184. Wang, E., Casciano, C. N., Clement, R. P., and Johnson, W. W. Inhibition of Pglycoprotein transport function by grapefruit juice psoralen. Pharm. Res., 18: 432-438, 2001.
185. Choi, C. H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell International, 5: 30-42, 2005.
186. Gottesman, M. M. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res, 53: 747-754, 1993.
187. Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., Lieber, M., Cossman, J., Gottesman, M. M., and Pastan, I. Expression of a multidrug resistance gene in human tumors. J. Natl. Canc. Inst., 81: 116-124, 1989.
188. Zhang, Y., Bachmeier, C., and Miller, D. W. In vitro and in vivo models for assessing drug efflux transporter activity. Adv. Drug Del. Rev., 55: 31-51, 2003.
189. Tiberghien, F., and Loor, F. Ranking of Pglycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anti-cancer Drugs, 7: 568-578, 1996.
190. Scala, S., Akhmed, N., Rao, U. S., Paull, K., Lan, L.-B., Dickstein, B., Lee, J.-S., Elgemeie, G. H., Stein, W. D., and Bates, S. E. P-Glycoprotein Substrates and Antagonists Cluster into Two Distinct Groups Mol. Pharmacol. Res., 51: 1024-1033, 1997.
191. Zamora, J. M., Pearce, H. L., and Beck, W. T. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Mol. Pharmacol., 33: 454-462, 1988.
192. Seelig, A., and Landwojtowicz, E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur. J. Pharm. Sci., 12: 31-40, 2000.
193. Hochman, J. H., Yamazaki, M., Ohe, T., and Lin, J. H. Evaluation of Drug Interactions with P-Glycoprotein in Drug Discovery: In Vitro Assessment of the Potential for Drug-Drug Interactions with P-Glycoprotein. Current Drug Metabolism, 3: 257-273, 2002.
194. Stouch, T. R., and Gudmundsson, O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev, 54: 315-328, 2002.
195. Muenster, U., Grieshop, B., Ickenroth, K., and Gnoth, M. J. Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm Res, 25: 2320-2326, 2008.
196. Dhainaut, A., Regnier, G., Tizot, A., Pierre, A., Leonce, S., Guilbaud, N., Kraus-Berthier, L., and Atassi, G. New purines and purine analogs as modulators of multidrug resistance. J. Med. Chem., 39: 4099-4108, 1996.
197. Beck, W. T., and Qian, X. D. Photoaffinity substrates for P-glycoprotein. Biochem. Pharmacol., 43: 89-93, 1992.
198. Kessel, D., Beck, W. T., Kukuruga, D., and Schulz, V. Characterization of multidrug resistance by fluorescent dyes. Cancer Res., 51: 4665-4670, 1991.
199. Schaich, M., Neu, S., Beck, J., Gekeler, V., Schuler, U., and Ehninger, G. A novel method for direct and fluorescence independent determination of drug efflux out of leukemic blast cells. Leukemia Res., 21: 933-940, 1997.
200. Balimane, P. V., Han, Y. H., and Chong, S. Current Industrial Practices of Assessing Permeability and P-Glycoprotein Interaction. The AAPS Journal 8: Article 1; E1-13, 2006.
201. Litman, T., Zeuthen, T., Skovsgaard, T., and Stein, W. D. Structure activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity Biochim. Biophys. Acta, 1361: 159-168, 1997.
202. Scarborough, G. A. Drug-stimulated ATPase activity of the human P-glycoprotein. J. Bioenerg. Biomembr., 27: 37-41, 1995.
203. Chen, C., Liu, X., and Smith, B. J. Utility of Mdr1-Gene Deficient Mice in Assessing the Impact of P-glycoprotein on Pharmacokinetics and Pharmacodynamics in Drug Discovery and Development. Current Drug Metabolism, 4: 272-291, 2003.